August 2010: Third and forth phase 3 trials were stated to have met primary and secondary endpoints.

The primary endpoint was sudden cardiac death, and the secondary endpoint was all-cause mortality.

Unfortunately the consecutive phase-III trial failed to show significant positive effects in the primary and secondary endpoints.

The consecutive phase-III trial of dimebon failed to show positive effects in the primary and secondary endpoints.

A secondary endpoint was postmenopausal weight gain.

It met the primary and both secondary endpoints.

No significant intervention effect was observed on the NTB executive function domain, a secondary endpoint of the study.

The secondary endpoint was histological improvement.

The effect on breast cancer incidence was a secondary endpoint and therefore should be judged with caution.

However, the committee voted 13-4 that the existing data supported a secondary endpoint of reducing the number of patients who chose liver transplantation.